Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448975 | 0.90 | CSNK2A1 (0.39) | EGFRSTK17ACSNK2A1SYKKCNN3 | |
| SCHEMBL3448702 | 0.89 | SYK (0.44) | ABL1BCREGFRMAPTSTK17A | |
| SCHEMBL3450030 | 0.89 | ABL1 (0.38) | ABL1BCREGFRSTK17ACRACR2A | |
| SCHEMBL3449000 | 0.89 | SYK (0.39) | EGFRSTK17ACRACR2ASYKKCNN3 | |
| SCHEMBL3448149 | 0.88 | BRAF (0.43) | ABL1BCRCSNK2A1 | |
| SCHEMBL3449308 | 0.87 | CSNK2A1 (0.36) | ABL1BCREGFRSTK17ACRACR2A | |
| SCHEMBL3451467 | 0.86 | JAK1 (0.39) | ABL1BCREGFRSTK17ACRACR2A | |
| SCHEMBL3449228 | 0.85 | SYK (0.36) | ABL1BCREGFRSTK17ACRACR2A | |
| SCHEMBL3451426 | 0.84 | JAK1 (0.36) | ABL1BCREGFRSTK17ACRACR2A | |
| SCHEMBL3448441 | 0.84 | LRRK2 (0.43) | ABL1BCRPTK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ABL1 370/4885BCR 3224/4885EGFR 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.